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Supplementary Fig. 1: Supra-hexoplot for % viability of CHO cells after treatment with 
compounds at 2 uM. Figure supplementary to Figure 2A. Compound identities, placement 





























Supplementary Fig. 2: Structural diversity of the MMV PRB compared to Malaria Clinical 
Drugs. MMV PRB (red dots) and Malaria Clinical Drugs (blue dots) chemical spaces are 
plotted in the Launched Drugs Space (beige dots). The Launched Drug Space is available 
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Supplementary Fig. 3: Gametocyte-specific compounds were enriched for azole antifungals, 
including MMV1634491 and MMV1634492, with dose-responses of these two compounds 
indicated after 48 h exposure to stage IV/V gametocytes and evaluated on the PrestoBlueÒ 
assay. Data are from three independent biological repeats (n=3), each performed in technical 




Supplementary Fig. 4: Inhibition of male gamete exflagellation in both direct or washout 
format. Figure supplementary to Figure 5B. Direct: compound added during induction of male 
exflagellation (30 min incubation), washout: stage V gametocytes treated with compound for 
48 h, compound washed out and male gamete exflagellation tested in absence of compounds. 
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Supplementary Fig. 5: Transmission-blocking activity (%TBA) on SMFA. Figure 
supplementary to Figure 5C. Data are from n=4 biological repeats, mean ± S.E. indicated 
























Supplementary Fig. 6: Endectocidal activity of 17 compounds with gametocytocidal activity. 
Compounds were screened at 2 µM and mortality of An. coluzzii (G3) determined after 4 
days, compared to Ivermectin (2 µM) as drug control, with DMSO (0.02%) as vehicle control. 
Data are from n=4 independent biological repeats (except for MMV1580488, MMV000043, 
MMV687237which is n=5 and MMV1634399, MMV1006203, MMV.1580483 and 









































































































































































































































































Supplementary Fig. 7:  Dose-response of MMV687273 (SQ109, 72 h pressure) against a 
PfNCR1-aptamer inducible knockdown line, where PfNCR1 expression is controlled by 
anhydrotetracycline (aTc), with wild type levels of PfNCR1 retained in presence of aTc 
(+aTc, 500 nM, 1.8 ± 0.08 µM), and PfNCR1 knock-down induced due to aTc removal (-aTc, 
2.43 ± 0.15 µM) (unpaired t-test p=0.0024). Data are from FACS analysis of parasitemia of 
acridine orange stained parasites, in triplicates (n=3), mean ± S.E. 95% confidence intervals 
on each point indicated as ribbons. Supplementary figure to Figure 7. 

























Supplementary Fig. 8: Sequence of the P. falciparum V-type H+-ATPase subunit A 
(PF3D7_1311900) with domains indicated in coloured bars underneath the sequence as per 
InterPro analysis https://www.ebi.ac.uk/interpro/protein/UniProt/Q76NM6/. The two mutation 






Mutation sites Q225, R353, bold, yellow
Walker A motif ( P-loop)
Non-homologous regulatory region
10         20         30         40         50
MTKVAVEKEE PGVVYKVAGS LVIAENMSGT RMYELAKVGW NKLVGEIIRL
60         70         80         90        100
EGNYAYIQVY EDTSGLSVGD PVIKTGNALS VELGPGILDN IYDGIQRPLE
110        120        130        140        150
RIANVCGDVY IYKGIDMTSL DHDKQWQFYA DKKLKLNDIV TGGDIFGFVD
160        170        180        190        200
ENKLFKEHKI MAPPNAKGRL TYIAPDGSYT LKDKIFELEY QGKKYTYGLS
210        220        230        240        250
HLWPVRDPRP VLEKVTGDTL LLTGQRVLDS LFPTVQGGTC AIPGAFGCGK
260        270        280        290        300
TCVSQALSKY SNSEVIIYVG CGERGNEMAE ILSDFPELTT KVDNEDVGIM
310        320        330        340        350
QRTCLVANTS NMPVAAREAS IYTGITLCEY FRDMGYNATM MADSTSRWAE
360        370        380        390        400
ALREISGRLA EMPADSGYPA YLGARLASFY ERAGKVKCIG SPSRIGSITI
410        420        430        440        450
VGAVSPPGGD FSDPVTTATM SIVQAFWGLD KKLAQRKHFP SVNWSTSFSK
460        470        480        490        500
YVRQLEQYFD NFDQDFLSLR QKISDILQQE SDLNDIVQLV GKDSLSEDQK
510        520        530        540        550
VVMEVAKIIR EDFLQQNAFS DYDYMCPLQK TVGMMRIICH FYAQCLRTLQ
560        570        580        590        600
EYDSRERKIG WGSIYNTLRP TINKITHMKF ENPKNSDEYF KKYFKALEEE
610 
ITVGLRNLME K
Supplementary table 1: Assay reproducibility for each assay platform (as described in the 
methods section) as evaluated by Z’-factor parameter according to the equation: 
Z’ = 1-[3(SD positive + SD background)/Mean positive – Mean background)]. ABS = asexual 
blood stages, GC = gametocyte. 
 
Assay platform  Z’-factor  
PfNf54 ABS pLDH colorimetric assay 0.63 
PfDd2 ABS SYBR Green I fluorescence 0.51 
PfNF54 GC ATP bioluminescence 0.864 
PfNF54 GC luciferase reporter assay 0.656 
PfNF54 GC PrestoBlue fluorescence 0.904 
Pb liver assay 0.44 
CHO MTT colorimetric 0.64 
HepG2 Cell-Titer Glo luminescence 0.52 
 
Supplementary table 2: 95% confidence intervals (CI) for IC50 values of the pan-reactive 
compounds Birinapant and AZD-0156. Supplementary data to Figure 3. 
  
MMV1557856  
(IC50, µM, ± S.E.) 
CI MMV1580483 
(IC50, µM, ± S.E.) 
CI 
ABS PfNF54 0.986 ± 0.055 0.8032-1.177 3.998 ± 0.799 2.667-4.161 
ABS PfDd2  0.236 ± 0.00 0.17-0.32 0.776 ± 0.079 0.56-1.06 
Pf stg IV/V gc 0.135 ± 0.001 0.1149-0.1749 0.236 ± 0.001 0.1983-0.277 
Pb liver stage  0.128 ± 0.011 0.0334-0.431 1.055 ± 0.035 0.584-5.47 
 
Supplementary table 3: Single nucleotide polymorphisms (SNPs) identified in SQ109-
resistant clones compared to the SQ109-sensitive 3D7 parent clone (270 ± 83 nM).  SNPs 
were found in the V-type H+-ATPase subunit A (Pf3D7_1311900) in all four clones, and in 
the AAA family ATPase (Pf3D7_0711000) for only two clones.  Quality refers to the phred-





















 R353K SQ2 686 ± 123 












SQ3 632 ± 41 
488912 1458.46 G T D687N 
SQ4 572 ± 37 
 
 
